Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2014-09-30
2017-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
NCT02327754
Uric Acid in Essential Hypertension in Children
NCT00288184
Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms
NCT04012294
Optimal Administration of Allopurinol in Dialysis Patients
NCT02477488
Uric Acid and the Endothelium in CKD
NCT01228903
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allopurinol
400 mg once daily, tablet treatment
Allopurinol
Placebo
Identical tablet treatment
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allopurinol
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Uric Acid ≥ 0,265 mmol/l
* GFR (glomerular filtration rate) \> 40 ml/min/1.73m2
Exclusion Criteria
* Recurrent renal calculi.
* Current use of azathioprine, 6-mercaptopurine, didanosine, tamoxifen, amoxicillin/ampicillin, or other drugs interacting with allopurinol.
* Known allergy to xanthine-oxidase inhibitors.
* Renal transplant.
* Non-diabetic kidney disease.
* Home, 24h og clinical BP\>180 or Diastolic BP \>130 mmHg at screening.
* Cancer treatment within two years before screening.
* History of hepatitis B or C.
* History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV) infection.
* History of alcohol or drug abuse.
* Breastfeeding or pregnancy or unwillingness to be on contraception throughout the trial.
* Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study.
* Serious pre-existing medical problems other than diabetes, e.g. congestive heart failure, pulmonary insufficiency.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peter Rossing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Rossing
Senior Principal Investigator, Professor, Chief Physician, DMSc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Steno Diabetes Center
Gentofte Municipality, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.